Answers are grounded in this paper and cite their sources.
Pleural disease management has in the past decade evolved from a primarily eminence-based space to an evidence-based one, owing to the unparalleled development of a robust, multicenter, and international research infrastructure, which has resulted in the publication of high-quality comparative clinical studies. From the optimal management of recurrent malignant pleural effusions to a paradigm shift in the way we approach pleural space infections, the breadth of quality data published in the past 10 years by a handful of expert coordinating centers across the globe has been a truly admirable and fundamentally informed clinical practice.1–3 The urgent need for the establishment of similar research networks by the interventional pulmonology community has lately been highlighted by the recent and unprecedented introduction of technologically advanced diagnostic and therapeutic platforms, often with limited or no evidence to support their use in clinical practice. Approval of these novel technologies has almost exclusively been obtained through a US Food and Drug Administration 510(k) clearance pathway that appears increasingly ill-suited to satisfy the necessarily stringent safeguards of safety and efficacy allowing optimal, patient-centered clinical decisions.4 In this context, the attempt at answering the very pragmatic research question of an optimal fluid drainage technique by Senitko and colleagues represents welcome steps in the right direction.5 Rather than settling for the usual retrospective study designs and their inherent biases, they designed a randomized controlled trial aimed to compare pleural fluid drainage using vacuum bottles versus aspiration with the provided one-way valve tubing system and syringe. The hypothesis tested was that manual drainage, because of the lesser negative pressures generated by manual aspiration, would result in less complications felt to be secondary to excessively negative pleural pressure such as chest discomfort, pneumothorax, and re-expansion pulmonary edema. While rare, these complications, extrapolated to an almost certainly underestimated 200,000 thoracenteses performed annually in the United States, represent a significant health care burden. In total, 100 patients were randomized, with well-balanced groups in terms of patient characteristics, and, interestingly, both primary endpoints, complication rates and early termination, were significantly higher in the vacuum bottle group, suggesting that manual aspiration may be a preferable, gentler drainage method. This study is significant in at least 2 important aspects. First, it satisfactorily meets the customary criteria of quality research question, that is, it appears a priori feasible (as a pragmatic study), interesting (if not for researchers, it certainly is for patients and clinicians), novel (it has never been rigorously studied), ethical (in that both arms are considered standard of care), and relevant (as thoracentesis is one of the most commonly performed pulmonary procedures). Second, and more importantly, it paves the way for future clinical trials, more complex in scope and methodology, by contributing to shifting the zeitgeist of clinical research in interventional pulmonology toward quality study designs, which will be needed to formally evaluate the utility of new technologies. It is also, indubitably and unfortunately, a step backwards, in that this study suffers from substantial limitations admittedly acknowledged by the authors. The lack of clearly defined endpoints, an insufficiently characterized hypothesis, the absence of power calculation based on available clinical data, and an uncertain presentation of the results, while rationalized by the authors as the necessary byproducts of a pilot feasibility study, ultimately leave the reader with a feeling of missed opportunity, as the equipoise seemingly remains intact. Nonetheless, the net result is a step in the right direction, and the authors should be commended for their effort. To address these types of limitations that have been rampant in the Interventional Pulmonary literature for decades, we have recently launched a research collaborative effort to facilitate the rapid roll-out of methodologically sound clinical research studies on a multicenter scale: the interventional pulmonology outcome group, or IPOG. This network has already been instrumental in advancing pleural research by allowing the completion of a multicenter randomized controlled trial on the use of routine manometry during therapeutic thoracentesis,6 and was recently extended to a larger number of recruiting sites for 2 randomized clinical trials evaluating distinct drainage methods: gravity-assisted versus suction-based drainage during thoracentesis (GRAVITAS, ClinicalTrials.gov Identifier: NCT03591952), and gravity versus vacuum-based indwelling tunneled pleural drainage system on pain (NEWTON), with over 18 centers involved in these 2 studies alone. The IPOG initiative has importantly led to the first dedicated Interventional Pulmonary project funded by the National Institute of Health and National Cancer Institute (R42CA141907) in a multicenter study investigating the outcomes of endobronchial injection of chemotherapy in patients with malignant airway obstruction (BROADWAY, ClinicalTrials.gov identifier: NCT02066103). Multiple other studies evaluating different aspects of pleural disease management and advanced diagnostic bronchoscopy, including a recently published multicenter randomized controlled trial comparing radial EBUS to standard fluoroscopy7 and a multicenter prospective clinical trial investigating the impact of electromagnetic bronchoscopy and transthoracic biopsy on diagnostic yield (ALL IN ONE, ClinicalTrials.gov identifier: NCT03338049),8 are at various stages of development. One anticipated key objective of this initiative is the ability to offer industry partners immediate access to a solid and proficient clinical research network in interventional pulmonology, in order to evaluate new technologies in a scientifically legitimate and timely manner, once introduced in the clinical space. Such unrestricted collaborations between industry and clinical researchers would benefit all parties involved, first and foremost, patients who often, with the current state of affairs, continue to bear the burden of procedural innovations.
No takes yet. Share an insight, caveat, or question.
Maldonado et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: